ClinicalTrials.gg
CompletedNCT03439891Updated Feb 11, 2025Results posted

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

A Phase 2 interventional study of Nivolumab and Sorafenib in Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 and Stage IIIB Hepatocellular Carcinoma AJCC v7, sponsored by Robin Kate Kelley. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Robin Kate Kelley · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.

Enrollment
39th of 53
16 · median 40
Started
2018
with 7 others
Phase 2
28 of 53
8 open now
Registered
13th of 53
by date

Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 39th largest by enrollment, is one of 8 that started in 2018, is one of 28 in phase 2, and was the 13th registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing nivolumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This phase II trial studies the best dose and side effects of sorafenib tosylate and nivolumab in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to nearby tissues or lymph nodes (locally advanced) or to other places in the body (metastatic). Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and nivolumab may work better in treating patients with liver cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. Maximum tolerated dose (MTD) of sorafenib tosylate (sorafenib) in combination with standard dose nivolumab with Child Pugh A-B7 liver function. (Part 1: Escalation Cohort).

II. Safety in participants with Child-Pugh B liver function. (Part 2: Child-Pugh B Escalation Cohort)

SECONDARY OBJECTIVES:

I. Safety and tolerability of combination overall. (Parts 1 and 2).

II. Rate of immune-related adverse event (irAE) for combination overall and in participants with Child-Pugh B liver function. (Parts 1 and 2).

III. Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in participants with Child-Pugh B liver function. (Parts 1 and 2).

IV. Duration of response (DOR), progression free survival (PFS), and overall survival (OS) for escalation cohort and Child-Pugh B expansion cohort and overall. (Parts 1 and 2).

EXPLORATORY OBJECTIVES:

I. Relationship between peripheral blood mononuclear cell (PBMC) immune cell subset frequencies, baseline liver function, and clinical outcomes.

II. Relationship between PBMC T cell receptor (TCR) clonotype frequency and diversity, baseline liver function, and clinical outcomes.

III. Tumor tissue immune cell subsets and TCR clonotype frequency and diversity in pre-treatment archival tumor tissue samples.

IV. Tumor and immune cell programmed death-ligand 1 (PD-L1) status in pre-treatment archival tumor tissue samples and relationship to clinical outcomes.

V. Changes in hepatitis B virus (HBV) and/or hepatitis C virus (HCV) viral load on treatment.

VI. Alpha-fetoprotein (AFP) changes on treatment and relationship to clinical outcomes.

VII. Relationship between clinical outcomes and clinicopathologic features including race/ethnicity, etiology of liver disease including HBV/HCV status, baseline liver function, presence of cirrhosis, macrovessel invasion, extrahepatic spread, site(s) of metastatic disease, prior treatment history including prior radiation and arterial therapies.

OUTLINE: This is a dose-escalation and expansion study of sorafenib tosylate.

DOSE-ESCALATION (Part 1):

Between 3-12 participants will be enrolled in Part 1. Participants receive sorafenib tosylate orally (PO) once daily (QD) or twice daily (BID) on days 1-28, and nivolumab intravenously (IV) over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

EXPANSION COHORT (Part 2).

Participants receive nivolumab IV over 30 minutes on days 1 and 15, and sorafenib tosylate once daily (QD) or twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30 and 100 days, then every 3 months for up to 2 years after the last dose.

03

Conditions studied

  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
  • Stage IIIB Hepatocellular Carcinoma AJCC v7
  • Stage IIIC Hepatocellular Carcinoma AJCC v7
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Hepatocellular Carcinoma AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologic or cytologic diagnosis of unresectable, locally advanced and/or hepatocellular carcinoma (HCC) not amenable to curative surgery, transplantation, or ablative therapies based upon assessment of treating investigator.

    a. For patients without prior histologic or cytologic diagnosis, radiographic diagnosis is allowed provided patients meet American Association for the Study of Liver Diseases (AASLD) criteria for radiographic diagnosis.

  2. Radiographically by (RECIST) version 1.1 in at least one site not previously treated with chemoembolization, radioembolization, radiation, or other local/liver-directed procedures (i.e. must have at least one measurable target lesion, either within the liver or in a measurable metastatic site); a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptable.
  3. Untreated/pretreatment must be available for correlative analyses
  4. Age at least 18 years at enrollment.
  5. (ECOG) 0 or 1 at enrollment
  6. At least 4 weeks after any prior chemoembolization, radioembolization, local ablative therapies, or hepatic radiation and recovery to =\< grade 1 treatment-related toxicity.
  7. At least 6 weeks after any major surgery including prior hepatic resection and recovery to =\< grade 1 treatment-related toxicity.
  8. At least 7 days after minor surgery (such as central venous access) or biopsy and recovery to =\< grade 1 treatment-related toxicity
  9. At least 2 weeks after any prior palliative radiation (e.g. to focal metastatic lesion such as bone metastases) and recovery to =\< grade 1 treatment-related toxicity.
  10. Blood pressure =\< 140/90 mm Hg with or without anti-hypertensive therapy

    a. Patients may be rescreened after initial ineligibility if due to elevated blood pressure, if adequately medically managed within approximately 30 days.

  11. Adequate baseline organ and marrow function as defined below:

    1. Adequate bone marrow function:

      • at least 1,200/microliter (mcL).
      • at least 50,000/mcL.
      • at least 9 g/dL.
    2. Adequate hepatic function:

      • Part 1: Total less than 2.6 mg/dL or 2 times (ULN), whichever is higher, and albumin at least 2.5 g/dL, if otherwise meets criteria for A or B7.
      • Part 2: Total bilirubin less than 3.9 mg/dL or 3 times ULN, whichever is higher, and albumin at least 2.0 g/dL, if otherwise meets criteria for Child Pugh B.
      • Both Parts: (AST) (serum glutamic-oxaloacetic transaminase (SGOT)) and alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)) less than 5 X ULN, (INR) less than 1.7.
    3. Creatinine less than 1. 5 X ULN and/or >= 60 mL/min.
  12. Child-Pugh A or B7 (Part 1); Child-Pugh B7-9 (Part 2).
  13. If surface antigen (sAg) and/or core antibody (Ab) positive, must be treated with appropriate antiviral therapy according to institutional practice with HBV deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR) less than 500 IU/mL.
  14. If clinical or histologic diagnosis of cirrhosis and/or clinical or radiographic evidence esophageal or gastric varices, must have had esophagogastroduodenoscopy (EGD) surveillance and adequate endoscopic therapy according to institutional standards.
  15. Able to swallow and retain oral medications
  16. Women of (WOCBP) must have a negative pregnancy test within 28 days before study enrollment.
  17. WOCBP and male partners of WOCBP must agree to use two methods of until at least 5 months after last dose of each study drug for WOCBP subjects, and 7 months for male partners of WOCBP.
  18. Able to understand and willingness to provide , and the willingness to comply with the requirements of the protocol.

    1. Subjects must have signed and dated an Institutional Review Board (IRB)/Independent Ethics Committees (IEC) approved written informed consent form in accordance with regulatory and institutional guidelines and before the performance of any protocol related procedures that are not part of standard of care.

Exclusion criteria

Exclusion Criteria:

  1. Any prior systemic therapy for HCC.
  2. Known fibrolamellar or mixed HCC-cholangiocarcinoma histology.
  3. Requirement for paracentesis to control ascites within 6 months before enrollment.

    a. Ascites which is not clinically detectable or mild on stable doses of diuretics during screening is allowed provided meets criteria for A or B7 (Part 1) or B7-9 (Part 2).

  4. Symptomatic hepatic encephalopathy requiring medication (such as lactulose or rifaximin) (Part 1) or any hospitalization for encephalopathy within 6 months before enrollment (Part 1 or 2).

    1. Hepatic encephalopathy that is adequately controlled on stable doses of lactulose and/or rifaximin per assessment of treating investigator is allowed in Part 2, provided no hospitalization for encephalopathy within 6 months before enrollment.
    2. Medications such as lactulose used for other indications (e.g. constipation) are allowed in both Part 1 and 2.
  5. History of upper gastrointestinal (GI) bleeding from esophageal and/or gastric varices within 12 months before enrollment.
  6. Requirement for systemic unless used for adrenal replacement, acute therapy for asthma or bronchitis exacerbation (=\< 2 weeks), or premedication for contrast allergy.

    a. Topical, intranasal, or inhaled steroids are not excluded.

  7. Active condition requiring systemic medication.
  8. Known (HIV) infection.
  9. Active coinfection with plus hepatitis delta (D) virus (HDV) or :

    1. Both hepatitis B and C as evidenced by detectable HBV surface antigen or HBV DNA and detectable HCV ribonucleic acid (RNA).
    2. Hepatitis D infection (HDV antibody positive) in subjects with detectable hepatitis B surface antigen or HBV DNA.
  10. Prior transplant of any solid organ or bone marrow/stem cells.
  11. Symptomatic hypothyroidism without replacement.

    a. Patients may be rescreened after initiating adequate replacement therapy

  12. History of seizure disorder requiring antiepileptic medication or with seizures.
  13. Non-healing wound, ulcer, non-healing traumatic bone fracture, or abscess within 30 days of enrollment.

    a. Nondisplaced, uncomplicated pathologic fracture due to tumor may be eligible provided adequately treated with radiation, surgery or other treatments with full recovery based upon investigator assessment.

  14. Central or necrotic lung .
  15. Known brain or .
  16. Uncontrolled hypertension (systolic pressure > 140 mm Hg and/or diastolic pressure > 90 mm Hg (National Cancer Institute (NCI)- (CTCAE) v4.0) on repeated measurement) despite optimal medical management.
  17. Active or cardiac disease including:

    1. Congestive heart failure - (NYHA) > class II.
    2. Active coronary artery disease including unstable or newly diagnosed angina or myocardial infarction within 6 months prior to study entry.
    3. Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.
    4. interval (QTc) (Fridericia) > 450 msec on two consecutive (ECGs) (baseline ECG should be repeated if QTc is found to be > 450 msec).
  18. Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 2 or higher within 6 months before first dose of study treatment any other hemorrhage/bleeding event of NCI-CTCAE v4.0 grade 3 or higher within 6 months before first dose of study treatment.
  19. Subjects with arterial or venous thrombotic or embolic, such as cerebrovascular accident (including ), myocardial infarction, or deep venous thrombosis (DVT) within 6 months of .

    1. Tumor or bland thrombus in hepatic vasculature is not an exclusion provided hepatic function criteria are met.
    2. Asymptomatic thromboembolic events such as incidentally-detected sub-segmental pulmonary emboli or superficial thromboses are not an exclusion provided the patient does not require treatment with therapeutic anticoagulation.
  20. Subjects who have used strong inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's wort (hypericum perforatum), dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days before first dose of study treatment.
  21. Subjects who require therapeutic anticoagulation or anti- therapy.

    1. Low dose aspirin (=\< 100 mg/day) is allowed
    2. Prophylactic doses of low molecular weight heparin (LMWH) are allowed if approved by study chair or designee.
  22. Subjects with any previously untreated and concurrent cancer that is distinct in primary site or histology from HCC except cervical cancer in-situ, treated nonmelanoma skin cancers, localized prostate cancer not requiring systemic therapy undergoing surveillance, or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than 2 years before enrollment are allowed provided that cancer therapy was completed at least 2 years prior to study entry (date of the informed consent form).
  23. Any uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring antibiotic therapy, pulmonary disease impairing functional status or requiring oxygen, impairment in gastrointestinal function that may affect or alter absorption of oral medications (such as malabsorption or history of gastrectomy or bowel resection), or uncontrolled diarrhea.
  24. Known or suspected allergy or to any of the study drugs, study drug classes, or of the formulations given during the course of this trial
  25. Women who are pregnant or breast-feeding at enrollment
  26. Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
  27. Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Part 1: Starting Dose Schedule (DL -1) Once a day

    Participants with Child-Pugh A or B7 receive a daily dose of 400mg sorafenib on days 1-28, and 240mg of nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dosing schedule.

    Biological: Nivolumab · Drug: Sorafenib

  • Experimental
    Part 1: Escalated Dose Schedule (DL 1) Twice a day

    Participants with Child-Pugh A or B7 receive a daily dose of 400mg sorafenib twice a day on days 1-28, and 240mg of nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dosing schedule.

    Biological: Nivolumab · Drug: Sorafenib

  • Experimental
    Part 2: Child-Pugh B (CPB) Expansion Cohort (sorafenib, nivolumab)

    Participants with Child-Pugh B7-9 receive sorafenib at the maximum tolerated dose (MTD) established in Part 1 on days 1-28, and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Biological: Nivolumab · Drug: Sorafenib

Interventions

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

  • Given PO

    Also known as: BAY 43-9006

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) (Part 1 Only)

    MTD is defined as the dose in which 1 or more dose limiting toxicities (DLT) is reported by study participants in Part 1 within the first cycle of treatment. Participants in Part 1 must receive at least 2 doses of nivolumab and at least 75% of sorafenib doses within 28 days (1 cycle), or experience a qualifying DLT event to be evaluable.

    Time frame: 28 days

  2. Proportion of Participants With Grade 3 or Higher Treatment-related Adverse Events (Part 2 Only)

    All adverse event (AE) will be summarized based on proportion of total participants in Part 2 to evaluate the safety of the treatment combination in participants with Child-Pugh B7-9 liver function as measured by proportion of participants with an AE of toxicity grade \>=3 as graded by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and assessed as at least possibly related to sorafenib, nivolumab, or the combination of therapies.

    Time frame: Up to 2 years

Secondary outcomes

  1. Proportion of Participants With Treatment-related Adverse Events

    Overall rates of AE and serious adverse events (SAE) as classified by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 assessed as at least possibly related to sorafenib, nivolumab, or the combination of therapies will be reported as the proportion of participants in each arm. .

    Time frame: Up to 2 years

  2. Proportion of Participants Reporting Immune-related Adverse Event (irAE) (Part 1 and Part 2 Combined)

    Safety events for all participants assessed by treating investigator and/or Study Chair as being at least possibly immune-related while on nivolumab (irAE) will be summarized based on proportion of total participants across all treatment groups combined.

    Time frame: Up to 2 years

  3. Proportion of Participants With Child-Pugh B (CPB) Reporting Immune-related Adverse Event (irAE) (Parts 1 and 2 Combined)

    Safety events for all CPB participants assessed by treating investigator and/or Study Chair as being at least possibly immune-related while on nivolumab (irAE) will be summarized based on proportion of total CPB participants across all treatment groups combined.

    Time frame: Up to 2 years

  4. Proportion of Participants With Dose Delays Due to Toxicity

    Delays in dosing due to adverse events will be summarized as proportion of participants by each arm.

    Time frame: Up to 2 years

  5. Proportion of Participants With Dose Reductions Due to Toxicity

    Dose reductions due to adverse events will be summarized as proportion of participants in each arm.

    Time frame: Up to 2 years

  6. Proportion of Participants Who Discontinued Treatment Due to Toxicity

    Treatment discontinuations due to adverse events will be summarized as proportion of participants in each arm.

    Time frame: Up to 2 years

  7. Proportion of Participants With an Objective Response (Part 1 and Part 2 Combined)

    Objective response is defined as the proportion of participants assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with measurable disease at study entry who have an evaluated complete response (CR) or partial response (PR) at any time during the main study. Participants with measurable disease at study entry who have unknown or missing response information will be treated as non-responders.

    Time frame: Up to 2 years

  8. Proportion of Participants With an Objective Response by Part

    Objective response will be based on assessments using RECIST 1.15 using local radiographic review and analyzed for Part 1 and Part 2 individually. Objective response is defined as the proportion of subjects with RECIST 1.1-measurable disease at study entry who have a CR or PR at any time during the main study. Participants with measurable disease at study entry who have unknown or missing response information will be treated as non-responders.

    Time frame: Up to 2 years

  9. Median Duration of Response (DOR) (Part 1 and Part 2 Combined)

    DOR is defined as the median time in months from first documented evidence of complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) until the first documented sign of disease progression or death for all participant who received any treatment during the course of the study.

    Time frame: Up to 2 years

  10. Median Duration of Response (DOR) by Treatment Group

    DOR is defined as the median time in months from first documented evidence of CR or PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) until the first documented sign of disease progression or death by treatment group for all participants who received treatment during the course of the study.

    Time frame: Up to 2 years

  11. Median Progression-Free Survival (PFS) (Part 1 and Part 2 Combined)

    PFS will be calculated as the median time in months from date of first dose of protocol therapy to date of first documented radiographic and/or clinical disease progression or death from any cause for all participants who received treatment during the course of the study. For participants who discontinued from study for other reasons than progression or death, PFS will be censored at the date last date known to be progression-free for up to 2 years following the last dose of protocol therapy.

    Time frame: Up to 3.5 years

  12. Median Progression-free Survival (PFS) by Child-Pugh Group

    PFS will be calculated as the median time in months from date of first dose of protocol therapy to date of first documented radiographic and/or clinical disease progression or death from any cause for participants grouped by Child-Pugh Group (Class A and Class B). For participants discontinued from study for other reasons than progression or death, PFS will be censored at the date last known to be progression-free for up to 2 years following the last dose of protocol therapy.

    Time frame: Up to 3.5 years

  13. Median Overall Survival (OS) (Part 1 and Part 2 Combined)

    OS is defined as the median time in months from the date of first dose of protocol therapy to the date of death due to any cause for up to 2 years following the last dose of protocol therapy. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. If data warrant, Kaplan-Meier estimates along with the 95% confidence intervals (CI) or full range will be reported.

    Time frame: Up to 3.5 years

  14. Overall Survival (OS) by Child-Pugh Group

    OS is defined as the median time in months from the date of first dose of protocol therapy to the date of death due to any cause for up to 2 years following the last dose of protocol therapy and will be reported for each of the Child-Pugh groups separately. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. If data warrant, Kaplan-Meier estimates along with the 95% confidence intervals (CI) or full range will be reported.

    Time frame: Up to 3.5 years

07

Results

Posted Feb 11, 2025
Limitations and caveats
The Part 2 Child Pugh B Expansion Cohort was closed to further accrual earlier than expected due to slow accrual resulting from a changing treatment landscape in hepatocellular carcinoma (HCC) with multiple new drug approvals.

Participant flow

Study Cohort Assignment
Participant flow — Study Cohort Assignment
MilestonePart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Started655
Completed655
Not completed000
Parts 1 & 2: All CPB Participants
Participant flow — Parts 1 & 2: All CPB Participants
MilestonePart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Started015
Completed015
Not completed000

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) (Part 1 Only)

MTD is defined as the dose in which 1 or more dose limiting toxicities (DLT) is reported by study participants in Part 1 within the first cycle of treatment. Participants in Part 1 must receive at least 2 doses of nivolumab and at least 75% of sorafenib doses within 28 days (1 cycle), or experience a qualifying DLT event to be evaluable.

Time frame:
28 days
Reported as:
Number · milligrams (mg) once per day
Maximum Tolerated Dose (MTD) (Part 1 Only)
milligrams (mg) once per dayPart 1: All Participants (Sorafenib, Nivolumab)
Maximum Tolerated Dose (MTD) (Part 1 Only)400
PrimaryProportion of Participants With Grade 3 or Higher Treatment-related Adverse Events (Part 2 Only)

All adverse event (AE) will be summarized based on proportion of total participants in Part 2 to evaluate the safety of the treatment combination in participants with Child-Pugh B7-9 liver function as measured by proportion of participants with an AE of toxicity grade \>=3 as graded by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and assessed as at least possibly related to sorafenib, nivolumab, or the combination of therapies.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With Grade 3 or Higher Treatment-related Adverse Events (Part 2 Only)
proportion of participantsPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Proportion of Participants With Grade 3 or Higher Treatment-related Adverse Events (Part 2 Only)0.6
SecondaryProportion of Participants With Treatment-related Adverse Events

Overall rates of AE and serious adverse events (SAE) as classified by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 assessed as at least possibly related to sorafenib, nivolumab, or the combination of therapies will be reported as the proportion of participants in each arm. .

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With Treatment-related Adverse Events
proportion of participantsPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Proportion of Participants With Treatment-related Adverse Events1.001.001.00
SecondaryProportion of Participants Reporting Immune-related Adverse Event (irAE) (Part 1 and Part 2 Combined)

Safety events for all participants assessed by treating investigator and/or Study Chair as being at least possibly immune-related while on nivolumab (irAE) will be summarized based on proportion of total participants across all treatment groups combined.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants Reporting Immune-related Adverse Event (irAE) (Part 1 and Part 2 Combined)
proportion of participantsAll Treatment Groups Combined (Sorafenib, Nivolumab)
Proportion of Participants Reporting Immune-related Adverse Event (irAE) (Part 1 and Part 2 Combined)0.94
SecondaryProportion of Participants With Child-Pugh B (CPB) Reporting Immune-related Adverse Event (irAE) (Parts 1 and 2 Combined)

Safety events for all CPB participants assessed by treating investigator and/or Study Chair as being at least possibly immune-related while on nivolumab (irAE) will be summarized based on proportion of total CPB participants across all treatment groups combined.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With Child-Pugh B (CPB) Reporting Immune-related Adverse Event (irAE) (Parts 1 and 2 Combined)
proportion of participantsParts 1 & 2: All CPB Participants
Proportion of Participants With Child-Pugh B (CPB) Reporting Immune-related Adverse Event (irAE) (Parts 1 and 2 Combined)0.83
SecondaryProportion of Participants With Dose Delays Due to Toxicity

Delays in dosing due to adverse events will be summarized as proportion of participants by each arm.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With Dose Delays Due to Toxicity
proportion of participantsPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)
Proportion of Participants With Dose Delays Due to Toxicity0.8331.000.8
SecondaryProportion of Participants With Dose Reductions Due to Toxicity

Dose reductions due to adverse events will be summarized as proportion of participants in each arm.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With Dose Reductions Due to Toxicity
proportion of participantsPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Proportion of Participants With Dose Reductions Due to Toxicity0.330.20.4
SecondaryProportion of Participants Who Discontinued Treatment Due to Toxicity

Treatment discontinuations due to adverse events will be summarized as proportion of participants in each arm.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants Who Discontinued Treatment Due to Toxicity
proportion of participantsPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Proportion of Participants Who Discontinued Treatment Due to Toxicity0.1670.200
SecondaryProportion of Participants With an Objective Response (Part 1 and Part 2 Combined)

Objective response is defined as the proportion of participants assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with measurable disease at study entry who have an evaluated complete response (CR) or partial response (PR) at any time during the main study. Participants with measurable disease at study entry who have unknown or missing response information will be treated as non-responders.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With an Objective Response (Part 1 and Part 2 Combined)
proportion of participantsAll Treatment Groups Combined (Sorafenib, Nivolumab)
Proportion of Participants With an Objective Response (Part 1 and Part 2 Combined)0.063
SecondaryProportion of Participants With an Objective Response by Part

Objective response will be based on assessments using RECIST 1.15 using local radiographic review and analyzed for Part 1 and Part 2 individually. Objective response is defined as the proportion of subjects with RECIST 1.1-measurable disease at study entry who have a CR or PR at any time during the main study. Participants with measurable disease at study entry who have unknown or missing response information will be treated as non-responders.

Time frame:
Up to 2 years
Reported as:
Number · proportion of participants
Proportion of Participants With an Objective Response by Part
proportion of participantsPart 1: Combined Escalation CohortsPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
Proportion of Participants With an Objective Response by Part0.090
SecondaryMedian Duration of Response (DOR) (Part 1 and Part 2 Combined)

DOR is defined as the median time in months from first documented evidence of complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) until the first documented sign of disease progression or death for all participant who received any treatment during the course of the study.

Time frame:
Up to 2 years
Reported as:
Median · months
Median Duration of Response (DOR) (Part 1 and Part 2 Combined)
monthsAll Treatment Groups Combined (Sorafenib, Nivolumab)
Median Duration of Response (DOR) (Part 1 and Part 2 Combined)4.2 (4.2 to NA)
SecondaryMedian Duration of Response (DOR) by Treatment Group

DOR is defined as the median time in months from first documented evidence of CR or PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) until the first documented sign of disease progression or death by treatment group for all participants who received treatment during the course of the study.

Time frame:
Up to 2 years
Reported as:
Median · months
Median Duration of Response (DOR) by Treatment Group
monthsPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)
Median Duration of Response (DOR) by Treatment Group4.2 (4.2 to NA)NA (NA to NA)NA (NA to NA)
SecondaryMedian Progression-Free Survival (PFS) (Part 1 and Part 2 Combined)

PFS will be calculated as the median time in months from date of first dose of protocol therapy to date of first documented radiographic and/or clinical disease progression or death from any cause for all participants who received treatment during the course of the study. For participants who discontinued from study for other reasons than progression or death, PFS will be censored at the date last date known to be progression-free for up to 2 years following the last dose of protocol therapy.

Time frame:
Up to 3.5 years
Reported as:
Median · months
Median Progression-Free Survival (PFS) (Part 1 and Part 2 Combined)
monthsAll Treatment Groups Combined (Sorafenib, Nivolumab)
Median Progression-Free Survival (PFS) (Part 1 and Part 2 Combined)2.58 (2.58 to NA)
SecondaryMedian Progression-free Survival (PFS) by Child-Pugh Group

PFS will be calculated as the median time in months from date of first dose of protocol therapy to date of first documented radiographic and/or clinical disease progression or death from any cause for participants grouped by Child-Pugh Group (Class A and Class B). For participants discontinued from study for other reasons than progression or death, PFS will be censored at the date last known to be progression-free for up to 2 years following the last dose of protocol therapy.

Time frame:
Up to 3.5 years
Reported as:
Median · months
Median Progression-free Survival (PFS) by Child-Pugh Group
monthsPart 1: Child-Pugh A Participants OnlyParts 1 and 2: Child Pugh B Participants (Sorafenib, Nivolumab)
Median Progression-free Survival (PFS) by Child-Pugh Group2.76 (2.76 to NA)2.58 (2.58 to NA)
SecondaryMedian Overall Survival (OS) (Part 1 and Part 2 Combined)

OS is defined as the median time in months from the date of first dose of protocol therapy to the date of death due to any cause for up to 2 years following the last dose of protocol therapy. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. If data warrant, Kaplan-Meier estimates along with the 95% confidence intervals (CI) or full range will be reported.

Time frame:
Up to 3.5 years
Reported as:
Median · months
Median Overall Survival (OS) (Part 1 and Part 2 Combined)
monthsAll Treatment Groups Combined (Sorafenib, Nivolumab)
Median Overall Survival (OS) (Part 1 and Part 2 Combined)12.99 (1.7 to 42)
SecondaryOverall Survival (OS) by Child-Pugh Group

OS is defined as the median time in months from the date of first dose of protocol therapy to the date of death due to any cause for up to 2 years following the last dose of protocol therapy and will be reported for each of the Child-Pugh groups separately. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis. If data warrant, Kaplan-Meier estimates along with the 95% confidence intervals (CI) or full range will be reported.

Time frame:
Up to 3.5 years
Reported as:
Median · months
Overall Survival (OS) by Child-Pugh Group
monthsPart 1: Child Pugh A ParticipantsPart 1 and 2: Child Pugh B Participants
Overall Survival (OS) by Child-Pugh Group15.26 (6.0 to 42)10.41 (1.7 to 36.2)

Adverse events

Collected over Up to 3.5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Starting Dose Schedule (DL -1) Once a Day5/6 (83.3%)4/6 (66.7%)6/6 (100%)
Part 1: Escalated Dose Schedule (DL 1) Twice a Day2/5 (40%)1/5 (20%)5/5 (100%)
Part 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)4/5 (80%)3/5 (60%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
HyperbilirubinemiaGastrointestinal disorders0/61/50/5
SepsisInfections and infestations0/60/51/5
Aspartate aminotransferase increasedInvestigations0/60/51/5
EncephalopathyNervous system disorders0/60/51/5
Transient ischemic attacksCardiac disorders0/60/51/5
Small intestinal obstructionGastrointestinal disorders1/60/50/5
Hip fractureInjury, poisoning and procedural complications1/60/50/5
HyperglycemiaMetabolism and nutrition disorders1/60/50/5
Rash maculo-papularSkin and subcutaneous tissue disorders1/60/50/5
Most frequent other events
Showing 10 of 94
Most frequent other events
EventPart 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion Cohort (Sorafenib, Nivolumab)
DiarrheaGastrointestinal disorders1/62/54/5
Rash maculo-papularSkin and subcutaneous tissue disorders3/62/53/5
Aspartate aminotransferase increasedInvestigations2/63/53/5
Alanine aminotransferase increasedInvestigations2/63/52/5
Blood bilirubin increasedInvestigations2/63/52/5
HypertensionVascular disorders3/60/53/5
NauseaGastrointestinal disorders3/60/51/5
Weight lossInvestigations3/60/50/5
AnorexiaMetabolism and nutrition disorders3/61/50/5
ConstipationGastrointestinal disorders1/62/52/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)Total
Mean64.3 ± 4.566 ± 11.467 ± 6.665.8 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)Total
Female1203
Male53513
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)Total
Hispanic or Latino0123
Not Hispanic or Latino64313
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)Total
American Indian or Alaska Native0000
Asian2417
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White3148
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)Total
United States65516
Child-Pugh Classification and Score
Child-Pugh Classification and Score(Participants)Part 1: Starting Dose Schedule (DL -1) Once a DayPart 1: Escalated Dose Schedule (DL 1) Twice a DayPart 2: Child Pugh B Expansion (Sorafenib, Nivolumab)Total
Child-Pugh A64010
Child-Pugh B0156
08

Study locations

2 sites
  • University of California, Davis
    Sacramento, California 95817, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Nov 2023, 67 months.

Results were first posted in Feb 2025, 1 year 2 months after primary completion.

Of 349 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's 67 months is above that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2018
First posted
Feb 20, 2018
StartActual
Apr 16, 2018
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Results first posted
Feb 11, 2025
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03439891
Lead sponsor
Robin Kate Kelley
Responsible party
Robin Kate Kelley (Associate Professor, University of California, San Francisco) — Sponsor-investigator
First posted
Feb 20, 2018
Start date
Apr 16, 2018
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Results posted
Feb 11, 2025
Last update
Feb 11, 2025

Study contacts

Robin K. Kelley, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Sorafenib

Start the discussion